Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is an exploratory computational study using machine learning to predict HDAC3 inhibition by FDA-approved drugs, without experimental validation or clinical data, raising mechanistic questions rather than answering therapeutic ones.
A narrative review evaluating translational barriers to p53-targeted therapy, raising mechanistic questions and proposing future directions rather than reporting a new trial result or establishing clinical efficacy.
In vitro enzyme inhibition study of organosulfur compounds against three targets; no cellular, animal, or clinical validation reported, and no comparison to established drugs or positive controls.
This is a narrative review synthesizing preclinical mechanistic evidence and proposing PSMD14 as a therapeutic target, but it does not report new empirical data, clinical trials, or outcomes in patients.
Structure-based computational discovery of a novel HDAC2 inhibitor with predicted superior binding and activity; lacks experimental validation in cells or organisms, representing early-stage hypothesis-generating work.
Mechanistic proof-of-concept in cell lines using CRISPR-dCas9 epigenetic editing, without in vivo validation or clinical outcomes, raising a therapeutic hypothesis rather than establishing efficacy.
Early-stage mechanistic study combining public database analysis, cell line knockdown, and mouse models with surrogate endpoints (proliferation, migration, bone metastasis incidence) but lacking human clinical validation of the proposed pathway.
Mechanistic study in genetically engineered mouse models identifying EED as a regulator of SCLC identity and LUAD-to-SCLC transformation; lacks clinical trial data or human validation beyond xenograft correlation.